Tumor-blocking role found for cell regulation molecule

In order to develop new anti-cancer treatments, researchers need to identify target molecules that are responsible for controlling tumour growth. Two such molecules are JNK and p38, which both regulate cell multiplication and cell death.

In a new project scientists from the Cancer Research UK Manchester Institute at The University of Manchester - part of the Manchester Cancer Research Centre - have investigated the role of a protein controlled by JNK and p38, known as ATF2, in tumour development.

Professor Nic Jones, leader of the Cell Regulation group and Director of the Manchester Cancer Research Centre, who led the study, said: "There have been conflicting findings in terms of whether JNK and ATF2 suppress or encourage tumour growth. We wanted to clarify their role in the development of cancer."

The researchers investigated a model of liver cancer and demonstrated that ATF2 appeared to suppress tumour growth. Further study showed that this process was dependent on JNK. They then examined molecules controlled by ATF2 and found that some of them were present in reduced levels in a number of different human tumours compared with normal cells.

This result suggests that ATF2 function is impaired during tumour development and indicates that its tumour suppression role may be more widespread than just liver cancer.

"We have demonstrated that JNK and ATF2 have a role to play in tumour suppression. Additional research is now needed to determine what causes changes in the levels of these ATF2-dependent molecules in tumours," added Professor Jones.

Suggested Articles

Dutch scientists used stem cells from CF patients to demonstrate a technique that corrects a mutation in the gene CFTR without having to cut DNA.

A new map of the thymus gland could help researchers understand how T cells develop and inspire treatments for cancer and autoimmune disease.

Brigham and Women’s Hospital scientists linked a noncoding RNA to atherosclerosis in a discovery that could aid in the development of new heart drugs.